

## DAFTAR PUSTAKA

1. Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol 2013;114:125-45.
2. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264-96.
3. Nissapatorn V , 2007. Toxoplasmosis: A Silent Threat in Southeast Asia . Research Journal of Parasitology, 2: 1-12.
4. Aditama N. Determinan Lingkungan Dan Perilaku Berhubungan Dengan Terjadinya Penyakit Infeksi Toxoplasmosis Di Wilayah Kota Semarang. J Kesehat Masy. 2016;4(5):67-76.
5. Nasrul, EY. Gambaran *Toxoplasma gondii* pada feses kucing di Kecamatan Padang Utara Kota Padang (skripsi). Fakultas Kedokteran Universitas Andalas. 2015:3.
6. Puteri ES. Hubungan jenis keganasan dengan kejadian toxoplasmosis pada pasien keganasan yang menjalani kemoterapi di rsup dr. M.djamil padang. Fakultas kedokteran universitas andalas. 2019.
7. Mendez OA, Koshy AA. *Toxoplasma gondii*: Entry, association, and physiological influence on the central nervous system. PLoS Pathog. 2017 Jul 20;13(7):e1006351
8. Tenter AM, Heckerroth AR, Weiss LM. *Toxoplasma gondii*: From animals to humans. Int J Parasitol. 2000;30(12-13):1217-58.
9. Peyron F, L'ollivier C, Mandelbrot L, et al. Maternal and congenital toxoplasmosis: diagnosis and treatment recommendations of a french multidisciplinary working group. Pathogens. 2019;8(1):1-15.
10. Bissati K El, Levigne P, Lykins J, et al. Global initiative for congenital toxoplasmosis : an observational and international comparative clinical analysis. Emerg Microbes Infect. Published online 2018.
11. Mboera LEG, Kishamawe C, Kimario E, Rumisha SF. Mortality Patterns of Toxoplasmosis and Its Comorbidities in Tanzania: A 10-Year Retrospective Hospital-Based Survey. 2019;7(February):1-7.
12. Liu Q, Wang ZD, Huang SY, et al. Diagnosis of toxoplasmosis and typing of *Toxoplasma gondii*. Parasit Vectors. 2015 May 28;8:292.
13. Beran O, Kodym P, Maly M, et al. The Effect of Latent *Toxoplasma gondii* Infection on the Immune Response in HIV-Infected Patients. Biomed Res Int. 2015;2015
14. Konstantinovic N, Guegan H, Stājner T, et al. Treatment of toxoplasmosis: Current options and future perspectives. Food Waterborne Parasitol. 2019;15
15. Robert-Gangneux F, Sterkers Y, Yera H, et al. Molecular diagnosis of toxoplasmosis in immunocompromised patients: A 3 -year multicenter retrospective study. J Clin Microbiol. 2015;53(5):1677-1684

16. Saadatnia G, Golkar M. A review on human toxoplasmosis. *Scand J Infect Dis.* 2012 Nov;44(11):805-14.
17. Wang Z, Liu H, Ma Z, et al. *Toxoplasma gondii* Infection in Immunocompromised Patients : A Systematic Review and. 2017;8(March):1-12.
18. Smit GSA, Lam T, Vu B, et al. Prenatal diagnosis and prevention of toxoplasmosis in pregnant women in Northern Vietnam : study protocol. Published online 2017:1-8.
19. Ayoade F, Joel Chandranesan AS. HIV-1 Associated Toxoplasmosis. In: *StatPearls.* Treasure Island (FL): StatPearls Publishing; 2020 Jan.
20. Report C. Toxoplasmic Encephalitis in an AIDS Patient with Normal CD4 Count: A Case Report. 2018;13(2):317-322.
21. Ibrahim M, Wegdan A, Abd M, Wahab E. *Toxoplasma gondii* in cancer patients receiving chemotherapy : seroprevalence and interferon gamma level. *J Parasit Dis.* 2019;43(3):464-471
22. Liu L, Wang P, Xu J, Xia C. *Acta Tropica* Increased risk of *Toxoplasma gondii* infection in cancer patients : A meta- analysis of current evidence based on case-control study. *Acta Trop.* 2019;192(December 2018):30-40.
23. Steele TA. Chemotherapy-induced immunosuppression and reconstitution of immune function. 2002;26:411-414.
24. Kheirandish F, Ezatpour B, Fallahi S, et al. *Toxoplasma* serology status and risk of miscarriage, a case-control study among women with a history of spontaneous abortion. *Int J Fertil Steril.* 2019;13(3):184-189.
25. Moncada PA, Montoya JG. Toxoplasmosis in the fetus and newborn: An update on prevalence, diagnosis and treatment. *Expert Rev Anti Infect Ther.* 2012;10(7):815-828. doi:10.1586/eri.12.58
26. Tammam AE, Haridy MAM, Abdellah AH, Ahmed SR, Fayed HM, Alsammani MA. Seroepidemiology of *Toxoplasma gondii* infection in women with first trimester spontaneous miscarriage in Qena Governorate, Egypt. *J Clin Diagnostic Res.* 2013;7(12):2870-2873.
27. Oz HS. Fetomaternal and Pediatric Toxoplasmosis. *J Pediatr Infect Dis.* 2017 Dec;12(4):202-208.
28. Kochanowsky JA, Koshy AA. *Toxoplasma gondii.* *Curr Biol.* 2018;28(14):R770-R771.
29. Dubey JP. History of the discovery of the life cycle of *Toxoplasma gondii.* *Int J Parasitol.* 2009;39(8):877-882.
30. Attias M, Teixeira DE, Benchimol M, Vommaro RC, Crepaldi PH, De Souza W. The life-cycle of *Toxoplasma gondii* reviewed using animations. *Parasites and Vectors.* 2020;13(1):1-13.
31. Zhang Y, Lai BS, Juhas M, Zhang Y. *Toxoplasma gondii* secret ory proteins and their role in invasion and pathogenesis. *Microbiol Res.* 2019;227(June):126293..
32. Retmanasari A, Widartono BS, Wijayanti MA, Artama WT. Prevalence and Risk Factors for Toxoplasmosis in Middle Java, Indonesia. *Ecohealth.*

- 2017;14(1):162-170.
33. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11(2):267-299.
  34. Sullivan WJ, Jeffers V. Mechanisms of *Toxoplasma gondii* persistence and latency. FEMS Microbiol Rev. 2012;36(3):717-733
  35. Martorelli Di Genova B, Wilson SK, Dubey JP et al. Intestinal delta-6-desaturase activity determines host range for *Toxoplasma gondii* sexual reproduction. PLoS Biol. 2019 Aug 20;17(8):e3000364
  36. Dumètre A, Dubey JP, Ferguson DJP, et al. Mechanics of the *Toxoplasma gondii* oocyst wall. Proc Natl Acad Sci U S A. 2013;110(28):11535-11540.
  37. Flegr J, Prandota J, Sovičková M, et al. Toxoplasmosis - A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014;9(3).
  38. Triana A. Faktor Determinan Toksoplasmosis Pada Ibu Hamil. J Kesehatan Masy. 2015;11(1):25.
  39. Muflikhah ND, Supargiyono, Artama WT. Seroprevalence and risk factor of toxoplasmosis in schizophrenia patients referred to grhasia psychiatric hospital, Yogyakarta, Indonesia. African J Infect Dis. 2018;12(Special Issue 1):76-82.
  40. Meerburg BG, Kijlstra A. Changing climate-changing pathogens: *Toxoplasma gondii* in North-Western Europe. Parasitol Res. 2009;105(1):17-24.
  41. Watts E, Zhao Y, Dhara A, Eller B, et al. Novel approaches reveal that *toxoplasma gondii* bradyzoites within tissue cysts are dynamic and replicating entities in vivo. MBio. 2015;6(5):1-24.
  42. Elizabeth VanWormera, 1, Heather Fritz, 1, Karen Shapiroa, b, 1, Jonna A.K. Mazeta A, Patricia A. Conrada B. Molecules to modeling: *Toxoplasma gondii* oocysts at the human–animal–environment interface. Bone. 2013;(1):28
  43. Lee S-B, Lee T-G. Toxoplasmic Encephalitis in Patient with Acquired Immunodeficiency Syndrome. Brain Tumor Res Treat. 2017;5(1):34.
  44. Valadkhani S. Toxoplasma encephalitis and AIDS in a patient with seizure and altered mental status: A case report. World J Emerg Med. 2017;8(1):65.
  45. Schlüter D, Barragan A. Advances and challenges in understanding cerebral toxoplasmosis. Front Immunol. 2019;10(FEB):1-13.
  46. Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013;112:1099-1101.
  47. Hampton MM. Congenital toxoplasmosis: A review. Neonatal Netw. 2015;34(5):274-278.
  48. Butler NJ, Furtado JM, Winthrop KL, et al. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013 Jan-Feb;41(1):95-108

49. Smith JR, Ashander LM, Arruda SL, Cordeiro CA, Lie S, Rochet E, Belfort R Jr, Furtado JM. Pathogenesis of ocular toxoplasmosis. *Prog Retin Eye Res.* 2020 Jul 24;100882.
50. Zhang K, Lin G, Han Y, et al. Serological diagnosis of toxoplasmosis and standardization. *Clin Chim Acta.* 2016 Oct 1;461:83-9
51. Soedarto. Masalah Titer IgG dan IgM dalam Menentukan Diagnosis Toksoplasmosis. *Ilmu Kedokteran Wijaya Kusuma.* 2017;6(2):1-5.
52. Park YH, Nam HW. Clinical features and treatment of ocular toxoplasmosis. *Korean J Parasitol.* 2013;51(4):393-399
53. Toxoplasmosis. CDC. 2018. Published online.
54. Tuda J, Adiani S, Ichikawa-Seki M, Umeda K, Nishikawa Y. Seroprevalence of *Toxoplasma gondii* in humans and pigs in North Sulawesi, Indonesia. *Parasitol Int.* 2017;66(5):615-618.
55. Vidal JE. HIV-Related Cerebral Toxoplasmosis Revisited: Current Concepts and Controversies of an Old Disease. *J Int Assoc Provid AIDS Care.* 2019;18:1-20.
56. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. *Int J Parasitol.* 2009 Jul 1;39(8):895-901.
57. Hwang S, Cobb DA, Bhadra R, Youngblood B, Khan IA. Blimp-1-mediated CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis. *J Exp Med.* 2016 Aug 22;213(9):1799-818.
58. Bobić B, Milosavić M, Guzijan G, Djurković-Djaković O. First Report on *Toxoplasma gondii* Infection in Bosnia and Herzegovina: Study in Blood Donors. *Vector Borne Zoonotic Dis.* 2016 Dec;16(12):807-809.
59. Hassana DS, Hadisaputro S, Achsan M, Sofro U. Toxoplasmosis and Cerebral Toxoplasmosis in HIV/AIDS Patients in Kariadi Hospital, Semarang. *J Epidemiol Kesehat Komunitas.* 2021;0(0):213-217.
60. Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. *Annu Rev Pathol.* 2011;6:223-48
61. Pereira-Chioccia VL, Vidal JE, Su C. *Toxoplasma gondii* infection and cerebral toxoplasmosis in HIV-infected patients. *Future Microbiol.* 2009 Dec;4(10):1363-79.
62. Qiao YC, Xu Y, Jiang DX, Wang X, Wang F, Yang J, et al. Epidemiological analyses of regional and age differences of HIV/AIDS prevalence in China, 2004–2016. *Int J Infect Dis.* 2019;81:215-220.
63. Vidal JE, Hernandez A V., Penalva De Oliveira AC, Dauar RF, Barbosa SP, Focaccia R. Cerebral toxoplasmosis in HIV-positive patients in Brazil: Clinical features and predictors of treatment response in the HAART era. *AIDS Patient Care STDS.* 2005;19(10):626-634.
64. Katabwa JK, Mukuku O, Kabika E, et al. Clinical and prognostic features of cerebral toxoplasmosis in HIV-infected patients in Lubumbashi , Democratic Republic of the Congo. 2021;11(3):79-82.
65. Parlog A, Schlüter D, Dunay IR. *Toxoplasma gondii*-induced neuronal alterations. *Parasite Immunol.* 2015 Mar;37(3):159-70.

66. Marra CM. Central nervous system infection with *Toxoplasma gondii*. *Handb Clin Neurol*. 2018;152:117-122.
67. Azovtseva OV, Viktorova EA, Bakulina EG, Shelomov AS, Trofimova TN. Cerebral toxoplasmosis in HIV-infected patients over 2015-2018 (a case study of Russia). *Epidemiol Infect*. 2020 May 4;148:e142.
68. Alvarado-Esquivel C, Pacheco-Vega SJ, Hernández-Tinoco J, Centeno-Tinoco MM, Beristain-García I, Sánchez-Anguiano LF, et al. Miscarriage history and *Toxoplasma gondii* infection: A cross-sectional study in women in Durango City, Mexico. *Eur J Microbiol Immunol (Bp)*. 2014 Jun;4(2):117-22.
69. Vishnevskia-Dai V, Achiron A, Buhbut O, Berar OV, Musika AA, Elyashiv SM, et al. Chorio-retinal toxoplasmosis: treatment outcomes, lesion evolution and long-term follow-up in a single tertiary center. *Int Ophthalmol*. 2020 Apr;40(4):811-821.
70. Greigert V, Bittich-Fahmi F, Pfaff AW. Pathophysiology of ocular toxoplasmosis: Facts and open questions. *PLoS Negl Trop Dis*. 2020;14(12):1-18.
71. Aleixo ALQ do C, Curi ALL, Benchimol EI, Amendoeira MRR. Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study. *PLoS Negl Trop Dis*. 2016;10(5):1-14.
72. Mushtaq F, Ahmad A, Qambar F, Ahmad A, Zehra N. Primary Acquired Toxoplasma Retinochoroiditis: Choroidal Neovascular Membrane as an Early Complication. *Cureus*. 2019;11(2).
73. Magliyah MSA, Al-Khars WI. Ocular toxoplasmosis related macular traction: A case report and review of the literature. *Saudi J Ophthalmol*. 2019;33(1):84-87.
74. Manuscript A, Therapy A. Update on Opportunistic Infections in the Era of Effective Antiretroviral Therapy Brian. 2015;28(3):501-518.
75. El-Sayed NM, Ramadan ME, Ramadan ME. *Toxoplasma gondii* Infection and Chronic Liver Diseases: Evidence of an association. *Trop Med Infect Dis*. 2016;1(1):1-8.
76. Gondal B, Aronsohn A. A Systematic Approach to Patients with Jaundice. *Semin Intervent Radiol*. 2016;33(4):253-258.
77. Ortiz-Alegría LB, Caballero-Ortega H, Cañedo-Solares I, Rico-Torres CP, Sahagún-Ruiz A, Medina-Escutia ME. Congenital toxoplasmosis: Candidate host immune genes relevant for vertical transmission and pathogenesis. *Genes Immun*. 2010;11(5):363-373.
78. Mayashinta DK, Halleyantoro R, Sari IP, Kurniawan A. Genotyping of *Toxoplasma gondii* in Cerebral and Ocular Toxoplasmosis. *J Trop Life Sci*. 2018;8(3):211-216.
79. Ali EN, Majeed SZ, Kadhem AA, Alubadi AEM. Prevalence of Toxoplasmosis As Coinfection in Iraqi Patients Infected With Tuberculosis. *Biochem Cell Arch*. 2019;19(2):3433-3437.
80. Ellis PK, Martin WJ, Dodd PJ. CD4 count and tuberculosis risk in HIV-

positive adults not on ART: A systematic review and meta-analysis. *PeerJ*. 2017;2017(12).

81. Desoubreaux G, Cabanne É, Franck-Martel C, Gombert M, Gyan E, Lissandre S, et al. Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: A single-centre prospective study assessing PCR-based diagnosis. *J Clin Pathol*. 2016;69(8):726-730.
82. Rey M-F, Mary C, Sanguinetti D, Ranque S, Bartoli C, L'Ollivier C. Successful Treatment of Pulmonary and Cerebral Toxoplasmosis Associated with Pneumocystis Pneumonia in an HIV Patient. *Diseases*. 2017;5(4):35.
83. Zoubi M Al, Zulfiqar B, Kulkarni M. Cerebral toxoplasmosis requiring urgent brain biopsy. *IDCases*. 2017;9(May):59-61.
84. Baker TL, Sun M, Semple BD, Tyebji S, Tonkin CJ, Mychasiuk R, Shultz SR. Catastrophic consequences: can the feline parasite *Toxoplasma gondii* prompt the purrfect neuroinflammatory storm following traumatic brain injury? *J Neuroinflammation*. 2020 Jul 25;17(1):222.